Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT05432596

Public ClinicalTrials.gov record NCT05432596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (AD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.

Study identification

NCT ID
NCT05432596
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Enrollment
250 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 10, 2022
Primary completion
Oct 25, 2023
Completion
Nov 13, 2023
Last update posted
Oct 25, 2024

2022 – 2023

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Aclaris Investigational Site Birmingham Alabama 35244
Aclaris Investigational Site Scottsdale Arizona 85255
Aclaris Investigational Site Bryant Arkansas 72022
Aclaris Investigational Site North Little Rock Arkansas 72117
Aclaris Investigational Site Encinitas California 92024
Aclaris Investigational Site Encino California 91436
Aclaris Investigational Site Castle Rock Colorado 80109
Aclaris Investigational Site Colorado Springs Colorado 80907
Aclaris Investigational Site Delray Beach Florida 33484
Aclaris Investigational Site Miami Florida 33173
Aclaris Investigational Site Miami Lakes Florida 33014
Aclaris Investigational Site Tampa Florida 33613
Aclaris Investigational Site West Palm Beach Florida 33401
Aclaris Investigational Site Sandy Springs Georgia 30328
Aclaris Investigational Site Normal Illinois 61761
Aclaris Investigational Site Skokie Illinois 60077
Aclaris Investigational Site Indianapolis Indiana 46250
Aclaris Investigational Site New Albany Indiana 47150
Aclaris Investigational Site West Lafayette Indiana 47906
Aclaris Investigational Site Baton Rouge Louisiana 70809
Aclaris Investigational Site Houma Louisiana 70364
Aclaris Investigational Site Saint Joseph Missouri 64506
Aclaris Investigational Site Wilmington North Carolina 28405
Aclaris Investigational Site Oklahoma City Oklahoma 73118
Aclaris Investigational Site Medford Oregon 97504
Aclaris Investigational Site Greenville South Carolina 29615
Aclaris Investigational Site Murfreesboro Tennessee 37130
Aclaris Investigational Site Arlington Texas 76011
Aclaris Investigational Site Dallas Texas 75230
Aclaris Investigational Site Houston Texas 77004
Aclaris Investigational Site San Antonio Texas 78213
Aclaris Investigational Site Richmond Virginia 23233

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05432596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 25, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05432596 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →